Kamada (KMDA) announced that the FDA has approved Kamada Plasma’s collection center in San Antonio, Texas. The approval was obtained following an on-site inspection made by the FDA during February. The center is now cleared to commence commercial sales of normal source plasma. The 11,100 square foot San Antonio facility supports up to 50 donor beds, with a planned capacity of approximately 50,000 liters per year at its full capacity, and is anticipated to be one of the largest collection centers for specialty plasma in the U.S.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMDA:
- Kamada Shifts $14.4 Million Dividend Payment Date to April 7, 2026
- Kamada Ltd’s Dependence on Investigator-Initiated Trials Poses Data Integrity and IP Risks to Its Long-Term Growth
- Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat
- Kamada Launches Annual Dividend Policy After Record 2025 Results
- Kamada reaffirms FY26 revenue view $200M-$205M
